Tag Archives: Johnson & Johnson

The New York Times reports: A Johnson & Johnson booster shot provided strong protection against the Omicron variant, greatly reducing the risk of hospitalization, according to a clinical trial in South Africa. The study, which compared more than 69,000 boosted health care workers with a corresponding group of unvaccinated South Africans, found that two shots of the vaccine reduced the …

Roll Call reports: Centers for Disease Control and Prevention vaccine advisers voted unanimously Thursday to recommend that the Johnson & Johnson COVID-19 vaccine take a back seat to Moderna and Pfizer shots, when possible, due to risks of adverse side effects. Serious clotting events, specifically thrombosis with thrombocytopenia, or TTS, are a rare but serious side effect of the Johnson …

CNBC reports: The Food and Drug Administration Wednesday night authorized booster shots of both Johnson & Johnson and Moderna’s Covid vaccines, another critical step in distributing extra doses to tens of millions of people. At the same time, U.S. regulators also authorized “mixing and matching” vaccines, allowing Americans to get a booster shot that’s a different vaccine from the one …

CNBC reports: An influential Food and Drug Administration advisory committee on Friday said the agency should authorize boosters of Johnson & Johnson’s single-shot Covid-19 vaccine to the more than 15 million Americans who have already received the initial dose. The unanimous vote – by the agency’s Vaccines and Related Biological Products Advisory Committee – is a critical step before the …

The New York Times reports: Johnson & Johnson is planning to ask U.S. federal regulators early this week to authorize a booster shot of its coronavirus vaccine, according to officials familiar with the company’s plans. The firm is the last of the three federally authorized vaccine providers to call for extra injections, amid mounting evidence that at least older adults …

The Associated Press reports: Johnson & Johnson released data showing that a booster dose to its one-shot coronavirus vaccine provides a strong immune response months after people receive a first dose. J&J said in statement Tuesday that it ran two early studies in people previously given its vaccine and found that a second dose produced an increased antibody response in …

Via press release from Johnson & Johnson: In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine. New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than …

Reuters reports: Johnson & Johnson is exploring a plan to offload liabilities from widespread Baby Powder litigation into a newly created business that would then seek bankruptcy protection, according to seven people familiar with the matter. J&J is now considering using Texas’s “divisive merger” law, which allows a company to split into at least two entities. For J&J, that could …

Courthouse News reports: An independent advisory panel for the U.S. Centers for Disease Control and Prevention voted Friday to recommend the continued use of the Johnson & Johnson Covid-19 vaccine after the single-dose jab was put on pause over blood clotting concerns. Friday’s vote followed similar concerns in the Europe Union over both the J&J jab and the AstraZeneca vaccine, …

The New York Times reports: Federal health agencies on Tuesday called for an immediate pause in use of Johnson & Johnson’s single-dose coronavirus vaccine after six recipients in the United States developed a rare disorder involving blood clots within about two weeks of vaccination. All six recipients were women between the ages of 18 and 48. One woman died and …

The Washington Post reports: President Biden intends to announce Wednesday that his administration will secure an additional 100 million doses of the single-shot vaccine developed by Johnson & Johnson, according to two officials familiar with the matter. He is expected to preview the plans at a Wednesday meeting with executives from Johnson & Johnson and Merck, just over a week …

The Washington Post reports: President Biden will announce Tuesday that pharmaceutical giant Merck & Co. will help make Johnson & Johnson’s single-shot coronavirus vaccine — an unusual pact between fierce competitors that could sharply boost the supply of the newly authorized vaccine, according to senior administration officials. Under the arrangement, Merck will dedicate two facilities in the United States to …

The New York Times reports: The Food and Drug Administration on Saturday authorized Johnson & Johnson’s single-shot Covid-19 vaccine for emergency use, beginning the rollout of millions of doses of a third effective vaccine that could reach Americans by early next week. The announcement arrived at a critical moment, as the steep decline in coronavirus cases seems to have plateaued …

NBC News reports: An independent advisory panel to the Food and Drug Administration voted Friday to recommend that the agency authorize Johnson & Johnson’s Covid-19 vaccine. Members of the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, voted unanimously in favor of recommending authorization. The FDA is not required to go along with the committee’s recommendation, but is widely …

CNBC reports: The Food and Drug Administration’s staff endorsed Johnson & Johnson’s Covid-19 vaccine for emergency use, a critical step in bringing a third shot to the U.S. marketplace. The staff report released Wednesday is meant to brief the FDA’s Vaccines and Related Biological Products Advisory Committee, which will meet Friday to review J&J’s request for emergency use authorization. The …

The Associated Press reports: Johnson & Johnson asked U.S. regulators late Thursday to clear the world’s first single-dose COVID-19 vaccine, an easier-to-use option that could boost scarce supplies. J&J’s vaccine was safe and offered strong protection against moderate to severe COVID-19, according to preliminary results from a massive international study. It didn’t appear quite as strong as two-dose competitors made …

The Wall Street Journal reports: Johnson & Johnson said its experimental Covid-19 vaccine was 66% effective at protecting people from moderate to severe disease in a large clinical trial, positive results that could pave the way for its deployment across the U.S. within weeks. The J&J vaccine also appeared to be generally safe and well tolerated among the 44,325 adults …

Reuters reports: Johnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot COVID-19 vaccine that potentially would simplify distribution of millions of doses compared with leading rivals using two doses. The company expects results of the Phase III trial by year end or early next year, Dr. Paul Stoffels, J&J’s chief scientific officer, said in a …

Reuters reports: Johnson & Johnson on Thursday kicked off U.S. human safety trials for its COVID-19 vaccine after releasing details of a study in monkeys that showed its best-performing vaccine candidate offered strong protection in a single dose. When exposed to the virus, six out of six animals who got the vaccine candidate were completely protected from lung disease and …

CNBC reports: Johnson & Johnson said Tuesday that it is discontinuing its talc-based baby powder in the United States and Canada as demand fell in light of mounting lawsuits that said it caused cancer. J&J attributed the decline “in large part to changes in consumer habits and fueled by misinformation around the safety of the product and a constant barrage …